Johnson & Johnson (JNJ) is Van Cleef Asset Management Inc’s 7th Largest Position
Van Cleef Asset Management Inc cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% during the third quarter, Holdings Channel reports. The institutional investor owned 77,505 shares of the company’s stock after selling 745 shares during the period. Johnson & Johnson makes up approximately 3.0% of Van Cleef Asset Management Inc’s portfolio, making the stock its 7th largest position. Van Cleef Asset Management Inc’s holdings in Johnson & Johnson were worth $9,156,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Horizon Investments LLC increased its position in Johnson & Johnson by 0.3% in the second quarter. Horizon Investments LLC now owns 2,349 shares of the company’s stock valued at $285,000 after buying an additional 8 shares in the last quarter. Landmark Financial Advisors LLC increased its position in Johnson & Johnson by 0.5% in the second quarter. Landmark Financial Advisors LLC now owns 1,979 shares of the company’s stock valued at $240,000 after buying an additional 9 shares in the last quarter. Blue Bell Private Wealth Management LLC increased its position in Johnson & Johnson by 0.3% in the third quarter. Blue Bell Private Wealth Management LLC now owns 4,856 shares of the company’s stock valued at $574,000 after buying an additional 15 shares in the last quarter. Lbmc Investment Advisors LLC increased its position in Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $457,000 after buying an additional 16 shares in the last quarter. Finally, Stratford Consulting LLC increased its position in Johnson & Johnson by 0.6% in the second quarter. Stratford Consulting LLC now owns 3,201 shares of the company’s stock valued at $388,000 after buying an additional 18 shares in the last quarter. 64.05% of the stock is owned by hedge funds and other institutional investors.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 114.99 on Friday. The firm has a 50-day moving average price of $114.46 and a 200-day moving average price of $118.30. The firm has a market cap of $312.83 billion, a price-to-earnings ratio of 20.18 and a beta of 0.72. Johnson & Johnson has a 52-week low of $94.28 and a 52-week high of $126.07.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.66 by $0.02. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The company earned $17.80 billion during the quarter, compared to analysts’ expectations of $17.71 billion. During the same period in the previous year, the firm posted $1.49 earnings per share. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. Analysts predict that Johnson & Johnson will post $6.71 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 14th. Investors of record on Tuesday, February 28th will be paid a $0.80 dividend. The ex-dividend date of this dividend is Friday, February 24th. This represents a $3.20 annualized dividend and a yield of 2.79%. Johnson & Johnson’s payout ratio is currently 56.64%.
COPYRIGHT VIOLATION WARNING: This piece of content was published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be read at http://www.dailypolitical.com/2017/01/13/johnson-johnson-jnj-is-van-cleef-asset-management-incs-7th-largest-position.html.
Several research analysts recently commented on the company. Credit Suisse Group reissued a “neutral” rating and issued a $123.00 price objective on shares of Johnson & Johnson in a research note on Monday, September 19th. RBC Capital Markets restated a “buy” rating and issued a $133.00 target price on shares of Johnson & Johnson in a report on Friday, January 6th. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $121.63 target price for the company in a report on Monday. Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday. Finally, Societe Generale restated a “hold” rating and issued a $116.00 target price on shares of Johnson & Johnson in a report on Sunday, October 23rd. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $122.22.
In other Johnson & Johnson news, Director Charles Prince bought 875 shares of the company’s stock in a transaction that occurred on Friday, October 21st. The stock was purchased at an average cost of $114.11 per share, for a total transaction of $99,846.25. Following the completion of the purchase, the director now owns 26,520 shares of the company’s stock, valued at approximately $3,026,197.20. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 0.11% of the stock is owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.